Nonsyndromic Retinal Dystrophy due to Bi-Allelic Mutations in the Ciliary Transport Gene IFT140

Sarah Hull, Nicholas Owen, Farrah Islam, Dhani Tracey-White, Vincent Plagnol, Graham E. Holder, Michel Michaelides, Keren Carrs, F. Lucy Raymond, Jean-Michel Rozet, Simon C. Ramsden, Graeme C. M. Black, Isabelle Perrault, Ajoy Sarkar, Mariya Moosajee, Andrew R. Webster, Gavin Arno, and Anthony T. Moore

1University College London Institute of Ophthalmology, London, United Kingdom
2Moorfields Eye Hospital, London, United Kingdom
3Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
4University College London Genetics Institute, London, United Kingdom
5Department of Haematology, University of Cambridge, Cambridge, United Kingdom
6NIHR BioResource—Rare Diseases, Department of Haematology, University of Cambridge, Cambridge, United Kingdom
7Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
8Laboratory of Genetics in Ophthalmology, INSERM UMR 1163, Paris Descartes-Sorbonne University, Imagine Institut, Paris, France
9Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, St Mary’s Hospital, Manchester, United Kingdom
10Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom
11Department of Clinical Genetics, Nottingham City Hospital, Nottingham, United Kingdom
12Ophthalmology, University of California, San Francisco, California, United States

Correspondence: Anthony T. Moore, Professorial Unit, Moorfields Eye Hospital NHS Trust, 162 City Road, London EC1V 2PD, UK; tony.moore@ucl.ac.uk. Gavin Arno; g.arno@ucl.ac.uk.
Submitted: August 17, 2015
Accepted: January 12, 2016

PURPOSE. Mutations in the ciliary transporter gene IFT140, usually associated with a severe syndromic ciliopathy, may also cause isolated retinal dystrophy. A series of patients with nonsyndromic retinitis pigmentosa (RP) due to IFT140 was investigated in this study.

METHODS. Five probands and available affected family members underwent detailed phenotyping including retinal imaging and electrophysiology. Whole exome sequencing was performed on two probands, a targeted sequencing panel of 176 retinal genes on a further two, and whole genome sequencing on the fifth. Missense mutations of IFT140 were further investigated in vitro using transient plasmid transfection of hTERT-RPE1 cells.

RESULTS. Eight affected patients from five families had preserved visual acuity until at least the second decade; all had normal development without skeletal manifestations or renal failure at age 13 to 67 years (mean, 42 years; median, 44.5 years). Bi-allelic mutations in IFT140 were identified in all families including two novel mutations: c.2815T>G (p.Asp939Glu) and c.1422_23insAA (p.Arg475Asnfs*14). Expression studies demonstrated a significantly reduced number of cells showing localization of mutant IFT140 with the basal body for two nonsyndromic mutations and two syndromic mutations compared with the wild type and a polymorphism.

CONCLUSIONS. This study highlights the phenotype of nonsyndromic RP due to mutations in IFT140 with milder retinal dystrophy than that associated with the syndromic disease. Keywords: retinitis pigmentosa, ciliopathy, next-generation sequencing

The outer segments of photoreceptors are highly modified, photosensitive cilia, which lack any capability for protein production.1 Thus, they are reliant on the intraflagellar transport (IFT) system, which comprises large protein complexes for transport from the cell body to ciliary tip and back driven by the motors kinesin-2 and dynein-2, respectively.2 The IFT-B complex is essential for ciliary assembly and anterograde transport, whereas the IFT-A complex is responsible for retrograde transport, with additional roles in anterograde transport by connecting kinesin to the IFT complex and in facilitating entry of proteins in to the cilium.3–4 IFT140, a subunit of IFTA, is vital for both the development and the maintenance of outer segments and has a specific role in opsin transport across the connecting cilium.5

Mutations in IFT140 have been associated with Jeune asphyxiating thoracic dystrophy and Mainzer-Saldino syndrome, ciliopathies forming part of a spectrum of skeletal dysplasias now collectively termed short rib thoracic dysplasia 9 with or without polydactyly (SRTD9, mendelian inheritance in man [MIM]#266920).5–7 First described in 1970, patients have variable skeletal features including shortened ribs, short stature, cone-shaped phalangeal epiphyses (prepubertal), brachymesophalangy, and acetabular spurring or metaphyseal defect of the femoral head.8 Nonskeletal features in the
Nonsyndromic Retinal Dystrophy due to Mutations in IFT140

majority of patients include a severe early-onset retinal dystrophy and end-stage renal failure secondary to nephropathy by the teenage years, with cerebellar ataxia, epilepsy, facial dysmorphism, learning difficulties, and cholesterol also reported.5–7

Retinitis pigmentosa (RP) is the most common form of inherited retinal dystrophy, with more than 60 genes associated with the nonsyndromic, recessive form.9–12 These include ciliopathy genes such as CEP290 and BBS1, which manifest both syndromic and nonsyndromic phenotypes.13,14 Recently, IFT140 mutations have been identified in patients with isolated retinal dystrophy.15,16 The present study reports eight patients from five families with isolated retinal dystrophy and bi-allelic IFT140 variants with detailed characterization of the ocular phenotype. Functional analysis of two of these variants with protein localization studies in hTERT-RPE1 cells supports their pathogenicity.

MATERIALS AND METHODS

The study protocol adhered to the tenets of the Declaration of Helsinki and received approval from the local ethics committees. Written informed consent was obtained from all participants prior to their inclusion in this study, with parental written consent provided on behalf of the children involved in this study.

Clinical Evaluation

Each proband with IFT140-related retinal dystrophy and available affected family members underwent a full clinical examination including visual acuity and dilated fundus examination. Retinal fundus imaging was obtained by conventional 35° fundus color photographs (Topcon Great Britain, Ltd., Berkshire, UK), fundus autofluorescence (AF) imaging using 30° or 55° Spectralis (Heidelberg Engineering, Ltd., Heidelberg, Germany) or ultra-widefield confocal scanning laser imaging (Optos plc, Dunfermline, UK), and either Stratus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA, USA) or Spectralis OCT (Heidelberg Engineering Ltd.). Full field and pattern electroretinography were performed using gold foil electrodes to incorporate the International Society for Clinical Electrophysiology of Vision (ISCEV) standards.17,18 Retinal function was performed in all available patients, with skeletal x-rays in five patients.

Molecular Investigations

Genomic DNA was isolated from peripheral blood lymphocytes using the Puregene kit (Gentra Puregene Blood Extraction Kit, Qiagen, Manchester, UK).

Patient 1.1 was initially negative for known retinal dystrophy variants using an arrayed primer extension (APEX)-based test (Asper Biotech, Ltd., Tartu, Estonia) using a genotyping microarray containing >300 disease causing variants and common polymorphisms for eight retinal dystrophy genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, RGPR1P1, LRAF, and MERTK) as previously described.19 He was then found negative by targeted next-generation sequencing (NGS) of the coding regions of 31 retinal dystrophy genes performed at the Bioscientia Center for Human Genetics (Ingelheim, Germany) using the Genome Sequerencer FLX system (Roche, Basel, Switzerland), enriched using a Roche/NimbleGen sequence capture and analyzed using Roche GS Reference Mapper (version 2.5.3) and JSI Medical Systems Software (version 3.5; Ettenheim, Germany). Whole exome sequencing (WES) was performed at AROS Applied Biotechnology using a solution-phase Agilent SureSelect 38-Mb exome capture (SureSelect Human All Exon Kit; Agilent Technologies, Inc., Santa Clara, CA, USA) and the Illumina HiSeq 2000 sequencer (Illumina, Inc., San Diego, CA, USA). Reads were aligned to the hg19 human reference sequence using Novoalign (Novocraft, Selangor, Malaysia), version 2.05. The ANNOVAR tool (Openbioinformatics.org) was used to annotate single nucleotide polymorphisms (SNPs) and small insertions/deletions.

Patient 2 was initially investigated as part of the UK National Collaborative Usher study due to the coexistence of hearing loss with retinal dystrophy with negative bi-directional Sanger sequencing of nine Usher genes (MYO7A, CDH23, PCDH15, USH1C, USH1G, USH2A, GPR98, WHRN, and CLRN1) and a candidate gene SLC4A7 as previously described.20 WES was then performed as above.

Patients 3.1 and 5 underwent NGS of the coding regions of 176 retinal genes at the Manchester Centre for Genomic Medicine (Manchester, UK) with enrichment using a SureSelect Target Enrichment Kit (Agilent Technologies, Inc.) and then sequenced on the HiSeq 2500 (Illumina, Inc.). Sequenced reads were aligned to the human reference sequence hg19 (build GRCh37) with the Burrows-Wheeler aligner (BWA v0.6.2).21 The genome analysis tool kit (GATK) v2.0.59 was used for base quality score recalibration and indel realignment prior to variant calling using the UnifiedGenotyper.22

Patient 4 underwent whole genome sequencing (WGS) as part of the National Institute for Health Research (NIHR) BioResource- Rare Diseases study using the Illumina TruSeq DNA PCR-Free Sample preparation kit (Illumina, Inc.) and sequenced using an Illumina HiSeq 2500, generating minimum coverage of 15× for approximately 95% of the genome. Reads were aligned to the Genome Reference Consortium human genome build 37 (GRCh37) using Isaac Genome Alignment Software (version 01.14; Illumina, Inc.).23 Single nucleotide variations and small insertion deletions were identified using Isaac Variant Caller (version 2.0.17).

Bi-directional Sanger sequencing of involved exons and intron-exon boundaries of IFT140 was performed on all patients and segregation confirmed in available relatives. DNA was amplified using specifically designed primers by polymerase chain reaction (PCR), and the resulting fragments were sequenced using standard protocols (information on request).

Nomenclature was assigned in accordance with GenBank accession number NM_014714.3 with nucleotide position 1 corresponding to the A of the ATG translation initiation codon. Variants were identified as novel if not previously reported in the literature and if absent from dbSNP, which is available at http://www.ncbi.nlm.nih.gov/projects/SNP/, NHLBI GO Exome Sequencing Project (ESP, Seattle, WA, USA), which is available at http://evs.gs.washington.edu/EVS/, 1000 genomes project, which is available at http://www.1000genomes.org/, and the Exome aggregation Consortium (ExAC; Cambridge, MA, USA), which is available at http://exac.broad institute.org. All were accessioned on November 25, 2015.24 The likely pathogenicity of novel missense variants was assessed using the predictive algorithms of sorting intolerant from tolerant (SIFT), available at http://sift.jcvi.org, and polymorphism phenotyping v2 (PolyPhen-2), available at http://genetics.bwh.harvard.edu/pph2, and the conservation of the residues throughout the species was analyzed using Clustal Omega, accessed at http://www.ebi.ac.uk/Tools/msa/clustalo/, with protein sequences identified from Ensembl, which was accessed at http://www.ensembl.org.25–28 Where relevant, potential splicing disruption was assessed using Splice Site Prediction by Neural Network at http://www.fruitfly.org/seq_tools/splice.html.29
Cell Transfection Studies

Site-directed mutagenesis using mutation-specific complementary primer pairs (Supplementary Table S1) generated four plasmid clones using pCMV-IFT140-Myc-DDK (RC207528; Origene, Rockville, MD, USA). Cultured hTERT-RPE1 cells were seeded at 1 × 10^5 cells/mL, and transient transfection was achieved using Lipofectamine LTX reagent with PLUS (Life Technologies, Paisley, UK). After incubation in OptiMEM-I reduced serum medium (Life Technologies) for 24 hours at 37°C in 5% CO_2, cells were fixed with 4% paraformaldehyde in PBS and then permeabilized with 0.5% Triton X-100 (Sigma-Aldrich, Inc., St. Louis, MO, USA) in PBS. Cells were immunostained with primary antibodies to the C-terminal Myc-DDK tag of the plasmid (1:5000 rat anti-DYKDDDDK tag antibody; 200475; Agilent Technologies) and basal body (1:1000 rabbit anti-pericentrin; Sigma-Aldrich, Dorset, UK); secondarily stained with 1:300 donkey Alexa Fluor 488-conjugated anti-rabbit (Life Technologies) and 1:300 donkey Alexa Fluor 647-conjugated anti-rabbit (Life Technologies); and mounted with ProLong Gold Antifade Mountant with DAPI (Life Technologies). Cells were imaged with confocal microscopy (Zeiss LSM 700; Carl Zeiss Microscopy, Ltd., Cambridge, UK). The percentage of transfected cells with localization of IFT140 to the basal body was calculated from a mean of three independent experiments with >100 cells counted per experiment (statistical analysis with a one-way analysis of variance and post hoc comparison using a Bonferroni correction; IBM SPSS Statistics version 22, IBM Corporation, New York, USA).

RESULTS

Ophthalmologic and Systemic Findings

Clinical details are summarized in Table 1, with clinical imaging described in Figure 1. All patients had a retinal dystrophy characterized by nyctalopia and progressive field loss, with fundus features and electrophysiology (available in three patients) consistent with RP.

Family 1 of Northern Pakistan origin was comprised of the proband (patient 1.1) and his affected second cousins; two of the three affected second cousins (patients 1.2 and 1.3) were available for clinical examination. Patient 1.1 was born at full term to consanguineous parents. He was noted to have reduced night vision at 2 years of age. Fundus examination demonstrated mild midperipheral retinal changes only (Fig. 1). Electroretinography (ERG) performed at age 8 demonstrated a relatively severe rod-cone dystrophy with marked bilateral macular involvement that had progressed when repeated at age 13 years. Systemically, patient 1.1 was well with no dysmorphic features. At age 15, his height was in the 50th–75th centile, weight in the 75th centile, and head circumference in the 25th centile. His fingers were noted to be long, and he had no skeletal abnormalities. Hand and hip x-rays were normal (Supplementary Fig. S1). He had a history of congenital right pelvico-ureteric junction obstruction and secondary hydropnephrosis, which required surgical correction at 4 years of age. Renal and liver function blood tests were normal at age 13 years, and renal ultrasound demonstrated a normal left kidney. On the right, there was global cortical thinning and loss of normal corticomedullary differentiation consistent with the history of hydropnephrosis.

Blood samples were obtained from all three affected second cousins of patient 1.1 to confirm segregation (Fig. 2). Assessment and investigation was possible for the two male patients: 1.2 and 1.3. Both developed visual symptoms in childhood with preservation of central vision until their 40s. Both had retinal changes of RP with attenuated vessels, macular atrophy, and midperipheral pigmentary change, which was worse in the older brother. Neither brother had any syndromic features. Specifically, hand x-rays did not demonstrate shortened phalanges, and renal and liver function was normal.

Patient 2, of Caucasian British origin, first noticed nyctalopia at age 16 years, with peripheral field loss noted in his mid-20s when he was diagnosed with RP. Loss of central vision occurred by 50 years of age, with fundus features of a severe and extensive pigmentary retinopathy. There was no history of skeletal or renal abnormalities. A hand x-ray did not identify shortened phalanges, and renal function blood tests were normal at age 67 years (Supplementary Fig. S1). There was a history of progressive hearing loss noted at the age of 4 years, which required hearing aids. Audiometry revealed symmetrical bilateral high-frequency loss and bilateral plateau loss of 25 to 30 dB in 250- to 2000-kHz frequencies. The hearing loss was atypical for Usher syndrome. There was no other medical history of note. His younger sister also has RP but without hearing loss. Clinical examination was not possible, but a DNA sample was obtained.

Family 3 is from the Gujarut region of India. The proband, patient 3.1, noted nyctalopia in his late 20s and problems with glare. He noted reduced left vision at age 44 years. Fundus examination revealed extensive pigmentary change and vessel attenuation. An ERG was consistent with severe generalized retinal dysfunction in both eyes. Patient 3.2 presented with nyctalopia and progressive peripheral field loss in her early 30s. When last reviewed at age 57, visual acuity was still good at 0.2 logMAR each eye (Snellen 20/32), despite marked vessel attenuation and generalized atrophy of the posterior pole. Neither patient has any systemic manifestations. Both patients have normal serum creatine but estimated glomerular filtration rates (GFRs) that are borderline and under review. Both are hypertensive on oral medications. Patient 3.2 has had stable creatinine and GFR over 6 years of monitoring. There was no other medical history of note. His younger sister also has RP but without hearing loss. Clinical examination was not possible, but a DNA sample was obtained.

Family 5 is British Caucasian. The proband noted difficulty with dark and light adaptation in his late 20s but otherwise remains without symptoms. At last review at age 31 years, the visual acuity was right 0.0 logMAR, left –0.1 logMAR, with mild retinal changes only. He was systemically well, with normal renal function and ultrasound. A skeletal survey was also normal.

Molecular Investigations

In family 1, WES identified a homozygous variant, c.1451C > T(p.Thr484Met), with segregation in five unaffected and three affected family members supporting causality (Table 2; Fig. 2). This variant has been previously reported.16 No other predicted pathogenic variants were identified in known retinal genes. In family 2, WES identified a splice site variant c.2399 þ 1G > T that has been previously reported in four syndromic patients and a novel missense variant, c.2815T > C (p.Ser939Pro) predicted to be tolerated in silico.5,6 Patient 2’s affected sister also carries both variants, with his son carrying the missense variant only, confirming that the mutations are in trans.5,6 A targeted gene panel of 176 genes identified an apparent homozygous variant c.998G > A(p.Cys333Tyr) in the third proband. This was also present in two other
<table>
<thead>
<tr>
<th>Patient</th>
<th>Age of Onset</th>
<th>Age at Last Review, logMAR Visual Acuity (Snellen), Refractive Error</th>
<th>Key Fundus Findings</th>
<th>Other Findings</th>
<th>ERG, PERG</th>
<th>Serum Creatinine (μmol/L) (70–120)</th>
<th>eGFR (mL/min/m²) (&gt;90 normal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 GC 17830</td>
<td>2 years</td>
<td>R 0.0 (6/6) L 0.0 (6/6) R +0.25/−1.25 ×40 L −5.50/−0.50 ×140</td>
<td>Midperipheral hypopigmented dots, mild RPE atrophy</td>
<td>Humphrey visual fields, 24-2: extensive loss of peripheral field, preserved central 10° Ishihara: R and L 17/17</td>
<td>Age 13, residual PERG activity, severe loss of both rod and cone systems</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>1.2 First decade</td>
<td>45 years</td>
<td>R 0.7 (6/30) L 0.5 (6/19)</td>
<td>Midperipheral RPE hypopigmentary change with intraretinal pigmentary migration, macular atrophy</td>
<td>Early cataract RE L cataract surgery age 44</td>
<td>Not done</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>1.3 First decade</td>
<td>44 years</td>
<td>R 0.3 (6/12) L 0.3 (6/12)</td>
<td>Midperipheral RPE hypopigmentation, early macular atrophy</td>
<td>Early lens opacity</td>
<td>Not done</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>2 GC 1558</td>
<td>16 years</td>
<td>R HM L PL</td>
<td>Posterior pole chorioretinal atrophy, extensive midperipheral pigmentation, severely attenuated vessels</td>
<td>Confrontation visual fields: &lt;5° BE Cataract surgery BE late 40s, myopic prior</td>
<td>Not done</td>
<td>76</td>
<td>95</td>
</tr>
<tr>
<td>3.1 GC 4303</td>
<td>Late 20s</td>
<td>R 0.7 (6/30) L 1.8 (1/60)</td>
<td>R cystoid macular edema with epiretinal membrane, B macular atrophy, attenuated vessels extensive pigmentary change</td>
<td>Confrontation visual fields: 20° on R, 10° on L Early cataract</td>
<td>Age 45, undetectable PERG and rod-specific ERG, markedly subnormal cone</td>
<td>115</td>
<td>61</td>
</tr>
<tr>
<td>3.2 Early 30s</td>
<td>57 years</td>
<td>R 0.2 (6/9.5) L 0.2 (6/9.5)</td>
<td>Marked vessel attenuation with nasally occluded vessels, extensive atrophy particularly of posterior pole, midperipheral pigmentary change</td>
<td>Early cataract BE Ishihara: R 2/17 L 4/17</td>
<td>Not done</td>
<td>91</td>
<td>56</td>
</tr>
<tr>
<td>4 GC 20552</td>
<td>14 years</td>
<td>R 0.3 (6/12) L 0.2 (6/9) R −2.50/−0.75 ×15 L −1.75/−1.25 ×10</td>
<td>Bilateral mild epiretinal membrane, mild RPE change in mid-periphery</td>
<td>Early subcapsular cataract Ishihara: R 7/17 L 17/17</td>
<td>Age 25, subnormal PERG, undetectable rod specific responses, subnormal cone</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>5 GC 21161</td>
<td>28 years</td>
<td>R 0.0 (6/6) L −0.1 (6/4.8)</td>
<td>Attenuated vessels, midperipheral RPE mottling</td>
<td>Confrontation visual fields: full Ishihara: R 17/17 L 17/17</td>
<td>Not done</td>
<td>77</td>
<td>109</td>
</tr>
</tbody>
</table>

eGFR, estimated glomerular filtration rate; GC, genetic family number; N, normal; NA, not available; PERG, pattern electroretinogram.
affected family members, with one unaffected sibling not harboring the variant; parental DNA was unavailable. It is therefore possible, in this nonconsanguineous family, that the affected patients are hemizygous with a deletion on the other allele. This variant has not been reported in an affected patient before but is present in 2 of 121,370 alleles on ExAC.

WGS identified the same homozygous variant in a fourth unrelated family (patient 4). Affected and unaffected family members overseas were unavailable for further testing.

FIGURE 1. Retinal imaging in IFT140-related retinal dystrophy: (a) color fundus photographs, (b) fundus autofluorescence, and (c) optical coherence tomography. Patient 1.1, age 13 years, right eye: (a) diffuse, midperipheral white dots with para-foveal early atrophy in the macula (arrow), (b) midperipheral reduced autofluorescence in area of white dots with central increased ring of increased autofluorescence in macula, and (c) centrally preserved inner segment ellipsoid (ISe) band. Patient 1.2, age 45 years, left eye: (a) central macula atrophy with peripheral intraretinal pigmented migration in regions of depigmentation. Patient 1.3, age 44 years, left eye: (a) central macular atrophy with midperipheral hypopigmentary dots. Patient 2, age 67 years, left eye: (a) posterior pole atrophy with heavy midperipheral pigmentary change, (b) extensive loss of autofluorescence throughout retina, particularly in midperiphery, and (c) extensive loss of outer retina and inner choroid. Patient 3.2, age 57 years, right eye: (a) macular atrophy, midperipheral RPE atrophy, and pigment change with marked vessel attenuation and vessel occlusion nasally, (b) widespread reduced autofluorescence particularly in posterior pole, and (c) disorganized retina with loss of outer retina and outer retinal tubulation (arrow). Patient 4, age 26 years, right eye: (a) mild midperipheral RPE atrophy, (b) ring of increased autofluorescence in macula with small dots of reduced autofluorescence nasally, and (c) ISe band preserved centrally in region corresponding to the FAF increased ring. Patient 5, age 30 years, right eye: (a) attenuated vessels, midperipheral RPE mottling/hypopigmentation, (b) ring of increased autofluorescence in the macula, speckled reduction in the midperiphery, and (c) ISe band preserved centrally.
Patient 5 also underwent targeted sequencing of 176 retinal genes, identifying two variants. The first, c.1021G>A (p.Ala341Thr), has an allele frequency of 10 in 119,692 on ExAC and is predicted to be damaging in silico (SIFT 0.03, Polyphen2 1.00). The second is a novel frameshifting mutation, c.1422_1423insAA (p.Arg475Asnfs*14). Segregation in his parents confirmed the mutations to be in trans.

Conservation of the missense variants identified in this study was compared to syndromic missense variants across a diverse range of orthologues (Supplementary Fig. S2). Ala341Thr, Thr484Met, and Ser939Pro are not conserved, and Cys333Tyr is fully conserved. Six of nine syndromic missense mutations are fully conserved, and three are not conserved.

**Localization of IFT140 and Mutants in hTERT-RPE1 Cells**

Site-directed mutagenesis using mutation-specific complementary primer pairs (Supplementary Table S1) generated four plasmid clones. Mutagenesis was confirmed by sequencing of the entire open reading frame. A total of six plasmids were used in cell transfection experiments: two contained nonsyndromic mutations c.1451C>T (p.Thr484Met, T484M) and c.2815T>C (p.Ser939Pro, S939P); one previously unreported mutation, c.1319T>C (p.Leu440Pro, L440P), from a patient with Leber congenital amaurosis and renal failure (Perrault I, written communication, 2015); a previously reported plasmid with a syndromic mutation c.1990G>A (p.Glu664Lys, E664K); the WT plasmid; and a polymorphism, c.2330T>G (p.Leu777Arg, L777R), rs34535263. Following transient transfection of IFT140 plasmids in hTERT-RPE1 cells and subsequent immunostaining, analysis of aberrant IFT140 localization with the basal body was performed (Fig. 3). Mean transfection efficiency was 38%, with generalized cytoplasmic staining frequently observed. Those cells with specific basal body labeling by IFT140 were counted. Statistically significant aberrant localization was found for T484M, S939P, L440P, and E664K compared with WT and L777R (P < 0.0001). No significant difference was found between T484M, S939P, L440P, and E664K compared with the syndromic mutants L440P and E664K.

**DISCUSSION**

This report describes the association of IFT140 mutations and nonsyndromic retinal dystrophy. A strength of this present study in addition to detailed ophthalmic phenotyping is the

![Figure 2. Pedigrees and variant segregation for the five families.](http://tvst.arvojournals.org/01/21/2018)

### Table 2. Summary of Molecular Results With Predicted Pathogenicity and Previous Reports

<table>
<thead>
<tr>
<th>Family</th>
<th>Variant</th>
<th>Predicted Effect</th>
<th>Sift Score</th>
<th>Polyphen2 Score</th>
<th>First Report in Patient</th>
<th>ExAC Database Allele Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>c.1451C&gt;T</td>
<td>p.Thr484Met</td>
<td>0.02</td>
<td>0.980</td>
<td>Xu 2015&lt;sup&gt;16&lt;/sup&gt;</td>
<td>5 of 120,980</td>
</tr>
<tr>
<td>2</td>
<td>c.2399+1G&gt;T</td>
<td>Abolish strong donor site</td>
<td>—</td>
<td>—</td>
<td>Perrault 2012&lt;sup&gt;5&lt;/sup&gt;</td>
<td>4 of 66,732</td>
</tr>
<tr>
<td>3 and 4</td>
<td>c.998G&gt;A</td>
<td>p.Cys333Tyr</td>
<td>1.00</td>
<td>0.991</td>
<td>Not reported</td>
<td>2 of 121,370</td>
</tr>
<tr>
<td>5</td>
<td>c.1021G&gt;A</td>
<td>p.Ala341Thr</td>
<td>0.03</td>
<td>1.000</td>
<td>Not reported</td>
<td>10 of 66,132</td>
</tr>
<tr>
<td>5</td>
<td>c.1422_23insAA</td>
<td>p.Arg475Asnfs*14</td>
<td>—</td>
<td>—</td>
<td>Novel</td>
<td>Not found</td>
</tr>
</tbody>
</table>
Figure 3. Aberrant localization of IFT140 with basal bodies in transiently transfected hTERTRPE1 cells. (A) Six Myc-DDK-tagged IFT140 plasmid constructs comprising wild type (WT) and five mutants: L440P (syndromic), T484M (nonsyndromic), E664K (syndromic), L777R (polymorphism), and S939P (nonsyndromic). Cells were immunostained with primary antibodies to the IFT140 plasmid (rat anti-DYKDDDDK Tag antibody), and basal body (rabbit anti-pericentrin) and secondarily stained with donkey anti-rat and donkey anti-rabbit. Cells were visualized with Zeiss confocal microscopy. Expressed IFT140 (white arrow) and basal body localization were reduced in all mutants compared with WT and a single nucleotide
systemic investigation of all but one patient, as well as including five patients in their fifth to seventh decades, which is far older than any previously reported patients. The patients have typical features of RP presenting from early childhood to the fourth decade, and all are developmentally normal, with no apparent skeletal or neurological abnormalities. Cone-shaped epiphyses are universally found prepubertally in IFT140-related syndromic disease. This abnormality is not apparent in adults, although shortening of the phalanges can still be detected. Prepubertal hand and pelvic x-rays in patient 1.1 were normal. In patients 1.2, 1.3, 2, and 5, hand x-rays did not identify shortened phalanges, but it remains possible that x-rays during childhood could have revealed evidence of the cone shape abnormality. Seven of eight patients were available for renal investigations. Renal function was normal except for patients 3.1 and 3.2, with borderline renal function at age 55 and 57 years, respectively. It is possible that this mild renal impairment is related to IFT140, but given their age and hypertension, it may be unrelated. Patient 1.1 had a unilateral congenital pelvico-ureteric obstruction surgically repaired. This abnormality has not been reported in IFT140-related disease, and the other kidney is structurally normal on ultrasound; it is likely that this is an incidental finding. His two older affected second cousins have normal renal function in their 40s.

All but one of the previously reported syndromic patients with IFT140 mutations had a severe, early-onset retinal dystrophy and undetectable or severely attenuated ERG.5–7 The exception, a patient homozygous for c.699T > G (p.Ile233Met), had no evidence of retinal dystrophy at age 2 years but did have skeletal and renal manifestations.5 Of seven patients recently reported with isolated retinal dystrophy due to IFT140, five have RP with onset of nystagopia ranging from 7 to 33 years old, and two have severe early-onset retinal dystrophy.15 There was no evidence of renal or skeletal involvement, but one patient had hypogonadism and fatty liver, which have been reported in other ciliopathies. It was not clear if all patients underwent systemic investigation and renal function. A further report of 12 patients focused on the ophthalmic phenotype, describing it as severe with infantile onset, hypertopia, and flat ERG (age, <2–20 years). The patients reported in this present study have milder and later onset retinal dystrophy than the majority of those previously reported with fundus features consistent with RP. Refraction available in two patients, was myopic.

All reported patients with syndromic forms of IFT140-related ciliopathy have developed end-stage renal failure by their second decade, with the exception of 10 families homozygous for p.Glu664Lys (reported ages, 10 months to 17 years).5–7,16 The affected children in these families presented in infancy with severe early-onset retinal dystrophy consistent with a diagnosis of Leber congenital amaurosis and with additional syndromic findings including epilepsy, hypotonia, and developmental delay. In all patients in whom hand x-rays were performed, cone-shaped epiphyses were identified. Systemic investigations were unavailable for four families.16 The lack of overt renal dysfunction suggests a possible genotype-phenotype correlation for this specific mutation.5–7,16 However, there has been one reported patient homozygous for this variant, with renal failure and kidney transplant age at 17 years, raising the possibility that renal dysfunction may still occur with this allele but perhaps later than with other syndromic disease alleles.16

Phenotypic heterogeneity of several ciliopathy genes has been well established, including CEP290, IQCB1, IFT172, BBS1, and BBS3.13,14,31–33 In the case of CEP290, there is evidence for a dosage-dependent phenotype with bi-allelic loss of function mutations associated with Joubert syndrome and the common c.2991+1655A > G splicing mutation, in which a small amount of protein is still produced, associated with Leber congenital amaurosis.13 In addition, CEP290 mutations in functionally critical regions, despite predicted residual protein production, were associated with a more severe phenotype.14 Three nonsyndromic families in this report have bi-allelic missense variants, as do several of the previously reported syndromic families (Supplementary Table S2).5–7 This would suggest that phenotypic variability is not related to the type of mutation. Only one patient with bi-allelic premature termination codons has been reported, which may indicate an essential developmental role for IFT140.16 Mice homozygous for IFT140+/− die midgestation, indicating embryonic lethality for a null phenotype.55

IFT140 is a 1462-amino-acid protein encoded by 31 exons and consists of two types of domain; five WD repeats and nine tetratricopeptide repeats.36 Reported mutations arise throughout the gene with no clustering or domain preference. Of the four missense variants in this report, p.Cys333Tyr and p.Ala541Thr arise within the WD5 domain but the other two are not located within known functional domains. Of the previously reported syndromic mutations, two arise within functional domains (p.Val292Met and p.Tyr511Cys in WD4) and the remaining seven do not. Conservation of missense amino acid residues in orthologues demonstrates a lack of conservation of three of the nonsyndromic residues, with one fully conserved. Three of nine syndromic mutations are not conserved, precluding any conclusion (Supplementary Fig. S2). The Cys333Tyr allele was identified in two families, and it would suggest that this may be a retina-specific allele. The variant Thr484Met was recently identified in conjunction with a second missense variant in a patient with nonsyndromic Leber congenital amaurosis, indicating that this allele may also be retina specific. The nonconserved Ala541Thr variant was identified in a patient with a novel frameshifting variant, which has not been reported in an affected patient before. The nonconserved Ser939Pro residue is predicted to be tolerated in silico and arises in conjunction with a splice site variant previously reported in syndromic disease. These results may indicate that the Ala541Thr and Ser939Pro variants are less deleterious to protein function such that there is a non-syndromic manifestation of disease.

Transient expression of IFT140 in hTERT-RPE1 cells transfected with a Myc-DDK-tagged IFT140 plasmid demonstrates localization of IFT140 with the basal body. This was significantly reduced in mutant cells compared with WT and L777R cells (P < 0.0001). No difference was found between the two missense variants from families in this report and the two reported syndromic missense variants, indicating a deleterious effect on protein trafficking in vitro for all mutants studied. This supports causality of these two nonsyndromic missense variants in vitro.
Nonsyndromic Retinal Dystrophy due to Mutations in IFT140

In this report, five families with apparently isolated RP due to IFT140 mutations are characterized. Given the potential for systemic complications, children with apparently isolated retinal dystrophy due to IFT140 mutations may need long-term systemic investigation and renal function monitoring. However, it is likely that some patients will have lifelong isolated retinal disease, and as more patients are reported, specific allele phenotypes may emerge.

Acknowledgments

The authors thank Sophie Saunier and Albane Bizet for the technical help with the cell transfection studies and the gift of the pCMV-IFT140-Myc-DDK and pCMV-IFT140-E664K-Myc-DDK plasmids.

Supported by the National Institute for Health Research England (NIHR) for supporting the NIHR BioResource–Rare Diseases (RG65966) and the Biomedical Research Centres at Moorfields (NIHR) for supporting the NIHR BioResource–Rare Diseases.

Disclosure: S. Hull, None; N. Owen, None; F. Islam, None; D. Tracey-White, None; V. Plagnol, None; G.E. Holder, None; M. Michaeclides, None; K. Cars, None; F.L. Raymond, None; J-M. Rozet, None; S.C. Ramsden, None; G.C.M. Black, None; I. Perrault, None; A. Sarkar, None; M. Moosajee, None; A.R. Webster, None; G. Arno, None; A.T. Moore, Sanofi (S), Oxford Biomedica (S), Sucampo Pharmaceuticals (S).

References


Downloaded From: http://tvst.arvojournals.org/ on 01/21/2018


